Galectin Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galectin Therapeutics Inc.
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Achieving superior stability profiles, leading to additional value propositions for development projects, is the aim of the game for Formycon and Leukocare under a new strategic development agreement.
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
- Drug Delivery
- Other Names / Subsidiaries
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.